Jan 11, 2012: SPEX today reported the successful completion of its 28-day rat toxicology study of its drug candidate, SPX-106.
Feb. 2, 2012: Spherix Announces Registered Direct Offering of $1.15 Million ===================================================== ========
10/24/11: Spherix today announced that SPX-106T (the combination of D-tagatose and SPX-106) reduced dyslipidemia in new studies of apolipoprotein E-deficient mice and Syrian Golden hamsters.
10/26/11: SPHERIX TO RAISE $1.25 MILLION IN PRIVATE PLACEMENT ===================================================== ===== Morning of Oct. 7, 2010: Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
Afternoon of Oct. 7, 2010: Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants ================================================ Morning of 11/16/09 - Spherix Announces Positive Interim Results In Phase 3 Trial of Novel, Oral Compound for Type 2 Diabetes
Afternoon of 11/16/09 - Spherix Incorporated to Raise $6.3 Million in Registered Direct Offering